Evgen Pharma PLC Appointment of Chief Medical Officer (4916W)
26 Aprile 2021 - 8:00AM
UK Regulatory
TIDMEVG
RNS Number : 4916W
Evgen Pharma PLC
26 April 2021
Evgen Pharma Plc
("Evgen" or "the Company")
Appointment of Chief Medical Officer
Evgen (AIM: EVG), a clinical stage drug development company
focused on the treatment of cancer, inflammation and acute
respiratory distress syndrome, announces that Glen Clack, MD, FFPM
will be joining the Company as Chief Medical Officer effective from
1 May 2021.
Dr Clack has over 30 years' experience in oncology and
translational medicine, and held various roles within AstraZeneca
for almost 20 years. Dr Clack has specialised in early phase
oncology clinical development with an emphasis on a number of
important cancers and has a wealth of experience in conducting and
managing clinical trials. He has successfully p rovided strategic
and operational leadership from Phase I through to regulatory
submissions and commercialisation. He has been a lead member of
study, clinical development and project teams on multiple
trials.
Glen is an Honorary Professor of Translational Medicine at the
University of Sheffield and an MSc Module Tutor and Honorary
Lecturer in Translational Science at the University of Manchester.
He has an MB BS from the Royal Free Hospital School of Medicine in
London, is a Fellow of the Faculty of Pharmaceutical Medicine at
the University of Wales and holds an MD from the University of
Sheffield.
Dr Huw Jones CEO of Evgen commented: "We are delighted to have
someone of Glen's experience and knowledge join our team. As we
progress further with our clinical programmes, Glen's depth of
understanding in the fields where we are active will be invaluable.
Glen will also be a key member of the team involved in leveraging
our relationships with our many partners. His unique skillset has
seen him take responsibility for a number of large, complex
projects and he has published over 50 academic papers on various
cancers."
Enquiries:
Evgen Pharma plc www.evgen.com via Walbrook
Barry Clare, Chairman
Richard Moulson, CFO
finnCap www.finncap.com +44 (0)20 7220 0500
Geoff Nash / Teddy Whiley (Corporate
Finance)
Alice Lane (ECM)
Walbrook PR +44 (0)20 7933 87870 or evgen@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7876
Paul McManus / Anna Dunphy 741 001
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company
developing sulforaphane based medicines for the treatment of
multiple diseases. The Company's core technology is Sulforadex(R),
a method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
Clinical data from the Company's open-label Phase II STEM trial
has shown that SFX-01 can halt the growth of progressing tumours in
patients with oestrogen-positive (ER+) metastatic breast cancer,
and in some cases significantly shrink the tumour, whilst causing
very few side effects.
The Company commenced operations in January 2008 and has its
headquarters at Alderley Park, Cheshire, and its registered office
is at the Liverpool Science Park, Liverpool. It is listed on the
AIM market of the London Stock Exchange and trades under the ticker
symbol EVG.
For further information, please visit: www.evgen.com
For research on the Company, please visit:
http://evgen.com/investors/analyst-coverage/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCDKNBDQBKDOQB
(END) Dow Jones Newswires
April 26, 2021 02:00 ET (06:00 GMT)
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Set 2023 a Set 2024